Brussels, 01/07/2010 (Agence Europe) - In its decision made on Case T-321/05, the European Court of Justice on Thursday 1 July essentially confirmed the decision made by the Commission on 15 June 2005 to fine the pharmaceutical group AstraZeneca Plc. (UK) and its Swedish subsidiary AstraZeneca AB a total amount of €60 million (€46 + €14 million) for the abuse of its dominant position and preventing the marketing of generic products replicating the anti-ulcer drug “Losec”....